Search

Your search keyword '"Luft, Thomas"' showing total 137 results
Start Over Author "Luft, Thomas" Search Limiters Academic (Peer-Reviewed) Journals
137 results on '"Luft, Thomas"'

1. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Schroeder, Thomas, Hamladji, Rose-Marie, Griskevicius, Laimonas, Salmenniemi, Urpu, Rambaldi, Alessandro, Mielke, Stephan, Kulagin, Alexander, Passweg, Jakob, Luft, Thomas, Gedde-Dahl, Tobias, Forcade, Edouard, Helbig, Grzegorz, Stelljes, Matthias, Castilla-Llorente, Cristina, Spyridonidis, Alexandros, Brissot, Eolia, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

5. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Author

Jost, Edgar, Schmid, Christoph, Baurmann, Herrad, Blau, Igor, Holderried, Tobias, Hertenstein, Bernd, Hänel, Mathias, Bornhäuser, Martin, Neidlinger, Helga, Kobbe, Guido, Winkler, Julia, Schroeder, Thomas, Bug, Gesine, Hopfer, Olaf, Finke, Jürgen, Hasenkamp, Justin, Krüger, William, Müller, Lutz, Kröger, Nikolaus, Eder, Matthias, Luft, Thomas, Hilgendorf, Inken, Ringhoffer, Mark, Stölzel, Friedrich, Scheid, Christoph, Platzbecker, Uwe, Wortmann, Friederike, Heinicke, Thomas, Wagner, Eva, Klein, Stefan, Burchert, Andreas, Tischer, Johanna, Stelljes, Matthias, Schäfer-Eckart, Kerstin, Wolff, Daniel, Junghanss, Christian, Ritter, Markus, Kaufmann, Martin, Bethge, Wolfgang, Mytilineos, Joannis, Einsel, Hermann, Sockel, Katja, Neu, Annika, Goeckenjan, Maren, Ditschkowski, Markus, Kröger, Nicolaus, Ayuk, Francis A., Stoelzel, Friedrich, Middeke, Jan Moritz, Bertz, Hartmut, Beverungen, David, von Bonin, Malte, Egger-Heidrich, Katharina, Heberling, Lisa, Trautmann-Grill, Karolin, Teipel, Raphael, Fraccaroli, Alessia, Fante, Matthias, Scheid, Christof, Holtick, Udo, Blau, Igor Wolfgang, Wulf, Gerald, Schwerdtfeger, Rainer, Kaun, Stephan, Winter, Susann, Theuser, Catrin, Beyersmann, Jan, Bornhaeuser, Martin, Schmeller, Sandra, and Schetelig, Johannes

Published
2024
Full Text
View/download PDF

9. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT

Author

Raj, Kavita, Eikema, Dirk-Jan, Sheth, Vipul, Koster, Linda, de Wreede, Liesbeth C., Blaise, Didier, Di Grazia, Carmela, Koc, Yener, Potter, Victoria, Chevallier, Patrice, Lopez- Corral, Lucia, Wu, Depei, Mielke, Stephan, Maertens, Johan, Meijer, Ellen, Huynh, Anne, Passweg, Jakob, Luft, Thomas, Pérez-Simón, Jose Antonio, Ciceri, Fabio, Piekarska, Agnieszka, Hayri Ozsan, G., Kröger, Nicolaus, Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

10. Computing solution spaces for gear box design.

Author

Ziegler, Klara, Demir, Kutay, Luft, Thomas, Mucks, Thomas, Fürst, Marius, Otto, Michael, Stahl, Karsten, Vogel-Heuser, Birgit, and Zimmermann, Markus

Subjects
DESIGN education, NEW product development, ENGINEERING design, GEARING machinery, MATHEMATICAL optimization
Abstract

The design of gear boxes is a complex challenge characterized by conflicting requirements and seemingly circular dependencies. Existing tools support engineers but focus on a single predefined design, often leading to costly iterative processes and non-optimal solutions. Solution Space Engineering (SSE) alleviates this by generating multiple designs represented by solution spaces. For this, a particular model structure is needed, and thus restructuring existing models, e.g., from industry standards. The application of solution spaces to a two-stage gear box is presented. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation

Author

Korell, Felix, Schreck, Nicholas, Müller-Tidow, Carsten, Dreger, Peter, Luft, Thomas, Liebregts, Tobias, and Schönland, Stefan

Subjects
Stem cells -- Transplantation, Infection, Health care industry
Abstract

Author(s): Felix Korell [sup.1], Nicholas Schreck [sup.2], Carsten Müller-Tidow [sup.1], Peter Dreger [sup.1], Thomas Luft [sup.1], Tobias Liebregts, Stefan Schönland, Ute Hegenbart, Aleksandar Radujkovic, Michael Schmitt, Axel Benner Author Affiliations: [...]

Published
2022
Full Text
View/download PDF

15. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Author

Gagelmann, Nico, Badbaran, Anita, Beelen, Dietrich W., Salit, Rachel B., Stölzel, Friedrich, Rautenberg, Christina, Becker, Heiko, Radujkovic, Aleksandar, Panagiota, Victoria, Bogdanov, Rashit, Christopeit, Maximilian, Park, Yong, Nibourel, Olivier, Luft, Thomas, Koldehoff, Michael, Corsten, Maarten, Heuser, Michael, Finke, Jürgen, Kobbe, Guido, Platzbecker, Uwe, Robin, Marie, Scott, Bart L., and Kröger, Nicolaus

Published
2021
Full Text
View/download PDF

16. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Author

Dreger, Peter, Dietrich, Sascha, Schubert, Maria-Luisa, Selberg, Lorenz, Bondong, Andrea, Wegner, Mandy, Stadtherr, Peter, Kimmich, Christoph, Kosely, Florentina, Schmitt, Anita, Pavel, Petra, Liebers, Nora, Luft, Thomas, Hegenbart, Ute, Radujkovic, Aleksandar, Ho, Anthony Dick, Müller-Tidow, Carsten, and Schmitt, Michael

Published
2020
Full Text
View/download PDF

19. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Author

Beelen, Dietrich Wilhelm, Trenschel, Rudolf, Stelljes, Matthias, Groth, Christoph, Masszi, Tamás, Reményi, Péter, Wagner-Drouet, Eva-Maria, Hauptrock, Beate, Dreger, Peter, Luft, Thomas, Bethge, Wolfgang, Vogel, Wichard, Ciceri, Fabio, Peccatori, Jacopo, Stölzel, Friedrich, Schetelig, Johannes, Junghanß, Christian, Grosse-Thie, Christina, Michallet, Mauricette, Labussiere-Wallet, Hélène, Schaefer-Eckart, Kerstin, Dressler, Sabine, Grigoleit, Goetz Ulrich, Mielke, Stephan, Scheid, Christof, Holtick, Udo, Patriarca, Francesca, Medeot, Marta, Rambaldi, Alessandro, Micò, Maria Caterina, Niederwieser, Dietger, Franke, Georg-Nikolaus, Hilgendorf, Inken, Winkelmann, Nils Rudolf, Russo, Domenico, Socié, Gérard, Peffault de Latour, Régis, Holler, Ernst, Wolff, Daniel, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Menzel, Helge, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, Grass, Sandra, Iori, Anna Paola, Finke, Juergen, Benedetti, Fabio, Pichlmeier, Uwe, Hemmelmann, Claudia, Tribanek, Michael, Klein, Anja, Mylius, Heidrun Anke, Baumgart, Joachim, Dzierzak-Mietla, Monika, and Markiewicz, Miroslaw

Published
2020
Full Text
View/download PDF

22. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Author

Pellagatti, Andrea, Armstrong, Richard N., Steeples, Violetta, Sharma, Eshita, Repapi, Emmanouela, Singh, Shalini, Sanchi, Andrea, Radujkovic, Aleksandar, Horn, Patrick, Dolatshad, Hamid, Roy, Swagata, Broxholme, John, Lockstone, Helen, Taylor, Stephen, Giagounidis, Aristoteles, Vyas, Paresh, Schuh, Anna, Hamblin, Angela, Papaemmanuil, Elli, Killick, Sally, Malcovati, Luca, Hennrich, Marco L., Gavin, Anne-Claude, Ho, Anthony D., Luft, Thomas, Hellström-Lindberg, Eva, Cazzola, Mario, Smith, Christopher W.J., Smith, Stephen, and Boultwood, Jacqueline

Published
2018
Full Text
View/download PDF

25. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Author

Schetelig, Johannes, de Wreede, Liesbeth C., van Gelder, Michel, Koster, Linda, Finke, Jürgen, Niederwieser, Dietger, Beelen, Dietrich, Mufti, G. J., Platzbecker, Uwe, Ganser, Arnold, Heidenreich, Silke, Maertens, Johan, Socié, Gerard, Brecht, Arne, Stelljes, Matthias, Kobbe, Guido, Volin, Liisa, Nagler, Arnon, Vitek, Antonin, Luft, Thomas, Ljungman, Per, Yakoub-Agha, Ibrahim, Robin, Marie, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

32. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group

Author

Schroeder, Thomas, Rachlis, Elena, Bug, Gesine, Stelljes, Matthias, Klein, Stefan, Steckel, Nina Kristin, Wolf, Dominik, Ringhoffer, Mark, Czibere, Akos, Nachtkamp, Kathrin, Dienst, Ariane, Kondakci, Mustafa, Stadler, Michael, Platzbecker, Uwe, Uharek, Lutz, Luft, Thomas, Fenk, Roland, Germing, Ulrich, Bornhäuser, Martin, Kröger, Nicolaus, Beelen, Dietrich W., Haas, Rainer, and Kobbe, Guido

Published
2015
Full Text
View/download PDF

34. Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation.

Author

Korell, Felix, DeFilipp, Zachariah, Schreck, Nicholas, Luft, Thomas, Mau, Marcela V., Benner, Axel, Dreger, Peter, Chen, Yi-Bin, and Müller-Tidow, Carsten

Subjects
STEM cell transplantation, SEPSIS, HEMATOPOIETIC stem cell transplantation
Abstract

Patient numbers for EASIX calculation are listed in following order (no neutropenic fever or sepsis / neutropenic fever without sepsis/neutropenic fever with sepsis) for the different timepoints: prior conditioning n = 125/200/27, day-3 n = 85/159/23, day 0 n = 84/159/23, day 3 n = 86/157/23, day 5 n = 87/153/22, day 7 n = 89/157/22, day 14 n = 108/161/20, day 21 n = 119/185/21, day 28 n = 120/194/17. As numbers of patients with sepsis were still small, these results warrant confirmation in larger multicenter trials with more sepsis patients. Sepsis patients were subgrouped by no neutropenic fever or sepsis, and neutropenic fever without and with sepsis. [Extracted from the article]

Published
2023
Full Text
View/download PDF

36. Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.

Author

Pabst, Caroline, Schreck, Nicholas, Benner, Axel, Hegenbart, Ute, Schönland, Stefan, Radujkovic, Aleksandar, Schmitt, Michael, Müller‐Tidow, Carsten, Orsatti, Laura, Dreger, Peter, and Luft, Thomas

Subjects
STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, ENDOTHELIUM diseases, INDOLEAMINE 2,3-dioxygenase, ADVERSE health care events, ENZYME metabolism
Abstract

Background: Allogeneic haematopoietic stem cell transplantation (alloSCT) often remains the only curative therapy for hematologic malignancies. Although the management of transplant‐associated adverse events considerably improved over the last decades, nonrelapse mortality (NRM) remains a challenge, and endothelial dysfunction was identified as a major contributor to NRM. Methods: Statin‐based endothelial prophylaxis (SEP) has been implemented in the standard of care in our transplant centre to reduce NRM caused by endothelial injury. Here, we retrospectively analysed the impact of SEP on clinical outcome in a cohort of 347 alloSCT patients. Results: SEP (n = 209) was associated with significantly reduced NRM (hazard ratio 0.61, 95% CI 0.38–0.96) and better overall survival (OS) after acute graft‐versus‐host disease (HR 0.59, 95% CI 0.37–0.93). Subgroup analyses showed that the NRM benefit was mainly found in patients with an intermediate endothelial activation and stress index (EASIX), while relapse risk was not affected. On day 100 post‐alloSCT, patients receiving SEP had significantly higher levels of the rate‐limiting enzyme of tryptophan metabolism, indoleamine 2,3‐dioxygenase (IDO), higher kynurenine to tryptophan ratios as a proxy of IDO activity and tended to have lower levels of the endothelial injury marker ST2 (p =.055). No significant differences in interferon‐gamma or IL18 levels were observed. These biomarker signatures suggest that the beneficial effects of SEP might be mediated by both endothelial protection and immunomodulation. Conclusions: Together, these data suggest that SEP improves NRM and OS post‐alloSCT in particular in patients with intermediate endothelial risk and provide first mechanistic clues about its potential mode of action. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study.

Author

Korell, Felix, Penack, Olaf, Mattie, Mike, Schreck, Nicholas, Benner, Axel, Krzykalla, Julia, Wang, Zixing, Schmitt, Michael, Bullinger, Lars, Müller-Tidow, Carsten, Dreger, Peter, and Luft, Thomas

Subjects
CELLULAR therapy, CYTOKINE release syndrome, CHIMERIC antigen receptors, COHORT analysis, PROGNOSIS
Abstract

Background: Endothelial dysfunction is associated with two main complications of chimeric antigen receptor T (CAR-T) cell therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This study evaluates the Endothelial Activation and Stress Index (EASIX) as a prognostic marker for high-grade CRS and ICANS in patients treated with CD19-directed CAR-T cells. Methods: In this retrospective study, a training cohort of 93 patients from the ZUMA-1 trial and a validation cohort of 121 patients from two independent centers (University Hospital Heidelberg, Charité University Medicine Berlin) were investigated. The primary objective was to assess the predictive capacity of EASIX measured immediately before the start of lymphodepletion (EASIX-pre) for the occurrence of grade ≥3 CRS and/or ICANS. To explore a possible endothelial link, serum levels of endothelial stress markers (angiopoietin-2, suppressor of tumorigenicity-2, soluble thrombomodulin, and interleukin-8) were determined before lymphodepletion and on day 7 after CART infusion in the validation cohort (n = 47). Results: The prognostic effect of EASIX-pre on grade ≥3 CRS and/or ICANS was significant in the training cohort [OR 2-fold increase 1.72 (1.26–2.46)] and validated in the independent cohort. An EASIX-pre cutoff >4.67 derived from the training cohort associated with a 4.3-fold increased odds ratio of severe CRS/ICANS in the independent cohort. Serum endothelial distress markers measured on day+7 correlated with EASIX-pre and associated with severe complications. Conclusions: EASIX-pre is a powerful predictor of severe CRS/ICANS after CD19-directed CART therapy and might be used as a basis for risk-adapted prevention strategies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.

Author

Mai, Elias K., Schmitt, Thomas, Radujkovic, Aleksandar, König, Laila, Goldschmidt, Hartmut, Ho, Anthony D., Luft, Thomas, Müller‐Tidow, Carsten, Dreger, Peter, Hegenbart, Ute, and Schönland, Stefan O.

Subjects
STEM cell transplantation, AUTOTRANSPLANTATION, ACUTE diseases, MULTIPLE myeloma, HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease
Abstract

Finally, other potential treatment options to reduce relapse/progression post alloSCT include post-transplantation cyclophosphamide (ptCy). Keywords: myeloma therapy; stem cell transplantation; cytogenetics EN myeloma therapy stem cell transplantation cytogenetics 244 248 5 12/27/21 20220101 NES 220101 Treatment of patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (autoSCT) remains challenging. Consequently, a future goal in MM therapy is to combine modern treatment concepts and alloSCT in suitable patients to reduce disease burden and enhance disease control in patients with relapsed high-risk MM. Details on re-induction treatment and response rates prior to alloSCT, engraftment and post alloSCT response rates, maintenance therapy, donor lymphocyte infusions (DLI) and relapse therapies are shown in Table I. The median age at alloSCT was 50 (range 34-64) years. [Extracted from the article]

Published
2022
Full Text
View/download PDF

49. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

Author

Shimoni, Avichai, Robin, Marie, Iacobelli, Simona, Beelen, Dietrich, Mufti, Ghulam J., Ciceri, Fabio, Bethge, Wolfgang, Volin, Liisa, Blaise, Didier, Ganser, Arnold, Luft, Thomas, Chevallier, Patrice, Schwerdtfeger, Rainer, Koster, Linda, de Witte, Theo, Kröger, Nicolaus, Nagler, Arnon, and Yakoub-Agha, Ibrahim

Subjects
HEMATOPOIETIC stem cell transplantation, MYELODYSPLASTIC syndromes, TREATMENT effectiveness, MULTIVARIATE analysis
Abstract

Summary: Allogeneic haematopoietic‐cell transplantation (allo‐HCT) is a potentially curative therapy for high‐risk myelodysplastic syndrome (MDS). Reduced‐intensity conditioning (RIC) is usually associated with lower non‐relapse mortality (NRM), higher relapse rate and similar overall‐survival (OS) as myeloablative‐conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced‐toxicity regimen with intense anti‐leukaemia activity and a favourable toxicity profile. We investigated post‐transplant outcomes in 1722 MDS patients following allo‐HCT with FT (n = 367), RIC (n = 687) or MAC (n = 668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0·001) but other disease characteristics were similar. The median follow‐up was 64 months (1–171). Five‐year relapse rates were 25% (21–30), 38% (34–42) and 25% (22–29), after FT, RIC and MAC, respectively, (P < 0·001). NRM was 30% (25–35), 27% (23–30) and 34% (31–38, P = 0·008), respectively. Five‐year OS was 50% (44–55), 43% (38–47), and 43% (39–47), respectively (P = 0·03). In multivariate analysis, FT was associated with a lower risk of relapse (HR 0·55, P < 0·001) and better OS (HR 0·72, P = 0·01). MAC was associated with higher NRM (HR 1·44, P = 0·001). In conclusion, FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved OS. FT may be the preferred regimen for allo‐HCT in MDS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results